What is the current stock price of Galectin Therapeutics Inc. (GALT)?

As of the latest market data, Galectin Therapeutics Inc. (GALT) is trading at $2.70. The stock has seen a loss of -3.23% today.

Does Galectin Therapeutics Inc. (GALT) pay a dividend?

Based on current data, Galectin Therapeutics Inc. does not have a confirmed active dividend policy.

What is the market cap of Galectin Therapeutics Inc.?

The current market capitalization of Galectin Therapeutics Inc. (GALT) is approximately unavailable.

GALT

Galectin Therapeutics Inc.·Healthcare

2.70

3.226%(−0.09)

Close Price

3.29

21.852%(+0.59)

After Hours

Last Updated: — ET

52W L: $1.2252W H: $7.13

GALT NEWS

globenewswire.com

19h ago

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin's Potential to Modify Disease Progression in Advanced MASH Cirrhosis

NORCROSS, Ga., May 27, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the oral and poster presentations of new analyses from its global NAVIGATE trial of belapectin at the European Association for the Study of the Liver (EASL) Congress 2026, taking place May 27–30, 2026, in Barcelona, Spain.

globenewswire.com

May 15

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

NORCROSS, Ga., May 15, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the three months ended March 31, 2026.

globenewswire.com

May 11

Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology

NORCROSS, Ga., May 11, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics Inc. (NASDAQ:GALT), a clinical-stage biotechnology company developing therapeutics that target galectin-3 for patients with MASH cirrhosis and portal hypertension, today announced the publication of results from its NAVIGATE Phase 2b clinical trial evaluating belapectin in patients with MASH cirrhosis and portal hypertension in AASLD flagship journal Hepatology.

globenewswire.com

Apr 27

Galectin Therapeutics, Inc. Investigated by the Portnoy Law Firm

LOS ANGELES, April 27, 2026 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Galectin Therapeutics, Inc., (“Galectin" or the "Company") (NASDAQ: GALT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F.

zacks.com

Apr 3

Galectin Therapeutics (GALT) Upgraded to Buy: What Does It Mean for the Stock?

Galectin Therapeutics (GALT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

defenseworld.net

Mar 27

Financial Analysis: Galectin Therapeutics (NASDAQ:GALT) & Phio Pharmaceuticals (NASDAQ:PHIO)

Phio Pharmaceuticals (NASDAQ: PHIO - Get Free Report) and Galectin Therapeutics (NASDAQ: GALT - Get Free Report) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, valuation, profitability, institutional ownership, analyst recommendations, dividends and risk. Volatility and Risk Phio Pharmaceuticals has a

Company Profile

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and development of small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Sector

Healthcare

Industry

Biotechnology

Employees

IPO Date

2002-09-04

Beta

0.45

Websitegalectintherapeutics.com↗